Si­lence Ther­a­peu­tics names David Horn Solomon as CEO

BioSpectrum (Asia) - - People News -

Si­lence Ther­a­peu­tics has an­nounced the ap­point­ment of Dr David Horn Solomon, an ex­pe­ri­enced pub­lic com­pany biotech boss and biotech in­vestor as its new chief ex­ec­u­tive of­fi­cer (CEO). Dr Solomon was pre­vi­ously the CEO of Zealand Pharma A/S, from 2008 to 2015, and has also been the CEO of Bionor Pharma ASA and Akari Ther­a­peu­tics.

Un­der his lead­er­ship, Zealand Pharma went pub­lic on NAS­DAQ OMX and its lead prod­uct, Adlixin, a GLP1 re­cep­tor ag­o­nist for the treat­ment of type II di­a­betes, was ap­proved in the US and glob­ally and is now mar­keted by French drugs firm Sanofi as a monother­apy and in com­bi­na­tion with Lan­tus as Soli­qua.

He has an ex­ten­sive ex­pe­ri­ence in phar­ma­col­ogy re­search. He has more than 20 years of ex­pe­ri­ence in med­i­cal re­search, health­care in­vest­ing and key bio­phar­ma­ceu­ti­cal & med­i­cal de­vice op­er­at­ing roles. He served lead­er­ship po­si­tions at sev­eral biotech­nol­ogy, phar­ma­ceu­ti­cal and med­i­cal de­vice com­pa­nies, in­clud­ing Crit­i­cal Di­ag­nos­tics.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.